Clinicopathological and Prognostic Significance of CXCR4 Expression in Osteosarcoma: a Meta-analysis

Overview

Journal Biomedicine (Taipei)

Specialty Biomedical Engineering

Date 2023 Feb 23

PMID 36816176

Authors

I Gusti Ngurah Ananda Wira Kusuma

Grace Yulia Alphani Yapson

John Nolan

I Gede Eka Wiratnaya

I Gede Putu Supadmanaba

Affiliations

Soon will be listed here.

Abstract

Background: C-X-C Motif Chemokine Receptor (CXCR4) is an oncogene that widely studied and associated with worse clinicopathological features and prognosis outcome on many types of cancer. Beside that, significance of CXCR4 expression on clinicopathological features and prognostic on osteosarcoma (OS) require further validation.

Aim: We conducted a meta-analysis to evaluate association between positive CXCR4 expression with clinicopathological features, and prognosis in OS.

Methods: Literature searches on Pubmed, Cochrane Library and Web of Science was conducted systematically up to December 2021 to find relevant references. Effect of CXCR4 expression on clinicopathological characteristic and prognostic were analyzed using Review Manager 5.4 (Cochrane Collaboration, Oxford, UK). Significance value less than 0.05 was considered statistically significant.

Results: By considering inclusion and exclusion criteria, 940 patients from 12 studies were suitable to included in qualitative analysis, and 10 studies were suitable for quantitative analysis. Association between CXCR4 expression and OS clinicopathological features was found significant on metastasis (OR = 4.01, 95%CI = 1.58-10.18; p = 0.003), stage (stage III & IV vs I & II, OR = 6.52, 95%CI = 1.05-40.62; p = 0.04), and tumor primary site (femur/tibia vs other, OR = 1.60, 95%CI = 1.04-2.45; p = 0.03), but not associated with histological type, gender, and age. Furthermore, CXCR4 expression is associated with poor overall survival in OS (HR = 2.13, 95%CI = 1.78-2.55; p < 0.001).

Conclusion: In conclusion, the results of our meta-analysis suggest that CXCR4 expression may be valuable as a histopathological predictor of poor clinicopathological features and prognosis of OS.

Citing Articles

Nerve growth factor promote VCAM-1-dependent monocyte adhesion and M2 polarization in osteosarcoma microenvironment: Implications for larotrectinib therapy.

Lin S, Yang S, Tsai C, Fong Y, Chen W, Liu J Int J Biol Sci. 2024; 20(11):4114-4127.

PMID: 39247831 PMC: 11379077. DOI: 10.7150/ijbs.95463.

Prospects and Advances in Adoptive Natural Killer Cell Therapy for Unmet Therapeutic Needs in Pediatric Bone Sarcomas.

Bareke H, Ibanez-Navarro A, Guerra-Garcia P, Gonzalez Perez C, Rubio-Aparicio P, Plaza Lopez de Sabando D Int J Mol Sci. 2023; 24(9).

PMID: 37176035 PMC: 10178897. DOI: 10.3390/ijms24098324.

References

Gunn W, Conley A, Deininger L, Olson S, Prockop D, Gregory C . A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells. 2005; 24(4):986-91. DOI: 10.1634/stemcells.2005-0220. View

Guo M, Cai C, Zhao G, Qiu X, Zhao H, Ma Q . Hypoxia promotes migration and induces CXCR4 expression via HIF-1α activation in human osteosarcoma. PLoS One. 2014; 9(3):e90518. PMC: 3949690. DOI: 10.1371/journal.pone.0090518. View

Zhao X, Wu Q, Gong X, Liu J, Ma Y . Osteosarcoma: a review of current and future therapeutic approaches. Biomed Eng Online. 2021; 20(1):24. PMC: 7923306. DOI: 10.1186/s12938-021-00860-0. View

Liao Y, Fu Z, Zhou C, Shan L, Wang Z, Yin F . AMD3100 reduces CXCR4-mediated survival and metastasis of osteosarcoma by inhibiting JNK and Akt, but not p38 or Erk1/2, pathways in in vitro and mouse experiments. Oncol Rep. 2015; 34(1):33-42. PMC: 4484610. DOI: 10.3892/or.2015.3992. View

Huang X, Zhao J, Bai J, Shen H, Zhang B, Deng L . Risk and clinicopathological features of osteosarcoma metastasis to the lung: A population-based study. J Bone Oncol. 2019; 16:100230. PMC: 6423404. DOI: 10.1016/j.jbo.2019.100230. View

Guan G, Zhang Y, Lu Y, Liu L, Shi D, Wen Y . The HIF-1α/CXCR4 pathway supports hypoxia-induced metastasis of human osteosarcoma cells. Cancer Lett. 2014; 357(1):254-264. DOI: 10.1016/j.canlet.2014.11.034. View

Ma Q, Zhou Y, Ma B, Chen X, Wen Y, Liu Y . The clinical value of CXCR4, HER2 and CD44 in human osteosarcoma: A pilot study. Oncol Lett. 2012; 3(4):797-801. PMC: 3362375. DOI: 10.3892/ol.2012.558. View

Lu Y, Guan G, Chen J, Hu B, Sun C, Ma Q . Aberrant CXCR4 and β-catenin expression in osteosarcoma correlates with patient survival. Oncol Lett. 2015; 10(4):2123-2129. PMC: 4579913. DOI: 10.3892/ol.2015.3535. View

Otsu K, Das S, Houser S, Quadri S, Bhattacharya S, Bhattacharya J . Concentration-dependent inhibition of angiogenesis by mesenchymal stem cells. Blood. 2008; 113(18):4197-205. PMC: 2676081. DOI: 10.1182/blood-2008-09-176198. View

10.

Kim S, Lee C, Midura B, Yeung C, Mendoza A, Hong S . Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis. 2007; 25(3):201-11. PMC: 2730112. DOI: 10.1007/s10585-007-9133-3. View

11.

Li Y, Dai Y, Zhang W, Li S, Tu C . Clinicopathological and prognostic significance of chemokine receptor CXCR4 in patients with bone and soft tissue sarcoma: a meta-analysis. Clin Exp Med. 2015; 17(1):59-69. DOI: 10.1007/s10238-015-0405-y. View

12.

Haydon R, Luu H, He T . Osteosarcoma and osteoblastic differentiation: a new perspective on oncogenesis. Clin Orthop Relat Res. 2006; 454:237-46. DOI: 10.1097/BLO.0b013e31802b683c. View

13.

Bianchi M, Mezzapelle R . The Chemokine Receptor CXCR4 in Cell Proliferation and Tissue Regeneration. Front Immunol. 2020; 11:2109. PMC: 7484992. DOI: 10.3389/fimmu.2020.02109. View

14.

Pollino S, Palmerini E, Dozza B, Bientinesi E, Piccinni-Leopardi M, Lucarelli E . CXCR4 in human osteosarcoma malignant progression. The response of osteosarcoma cell lines to the fully human CXCR4 antibody MDX1338. J Bone Oncol. 2019; 17:100239. PMC: 6543022. DOI: 10.1016/j.jbo.2019.100239. View

15.

Laverdiere C, Hoang B, Yang R, Sowers R, Qin J, Meyers P . Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res. 2005; 11(7):2561-7. DOI: 10.1158/1078-0432.CCR-04-1089. View

16.

Zhao H, Guo L, Zhao H, Zhao J, Weng H, Zhao B . CXCR4 over-expression and survival in cancer: a system review and meta-analysis. Oncotarget. 2015; 6(7):5022-40. PMC: 4467131. DOI: 10.18632/oncotarget.3217. View

17.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

18.

Lin F, Zheng S, Shen Z, Tang L, Chen P, Sun Y . Relationships between levels of CXCR4 and VEGF and blood-borne metastasis and survival in patients with osteosarcoma. Med Oncol. 2010; 28(2):649-53. DOI: 10.1007/s12032-010-9493-4. View

19.

Mardani A, Gheytanchi E, Mousavie S, Madjd Jabari Z, Shooshtarizadeh T . Clinical Significance of Cancer Stem Cell Markers CD133 and CXCR4 in Osteosarcomas. Asian Pac J Cancer Prev. 2020; 21(1):67-73. PMC: 7294029. DOI: 10.31557/APJCP.2020.21.1.67. View

20.

Beckermann B, Kallifatidis G, Groth A, Frommhold D, Apel A, Mattern J . VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma. Br J Cancer. 2008; 99(4):622-31. PMC: 2527820. DOI: 10.1038/sj.bjc.6604508. View